MedTrace Logo

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

NCT04825834 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2992

Last updated 2025-08-08

No results posted yet for this study

Summary

The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.

Conditions

Interventions

OTHER

Blood Sample Collection

Subjects enrolled in the DELFI-L101 will have blood specimens collected (\~40 mL) at enrollment.

Sponsors & Collaborators

  • Delfi Diagnostics Inc.

    lead INDUSTRY

Principal Investigators

  • Peter Mazzone, MD, MPH · The Cleveland Clinic

  • Luke RG Pike, MD, DPhil · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-22
Primary Completion
2025-07-15
Completion
2025-07-15

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04825834 on ClinicalTrials.gov